

Commercial ASC Outpatient Claim Example



Black = Required Blue = Situational/Required, if applicable Forest Lake ASC STATEMENT COVERS PERIOD FED. TAX NO 123 Vista Ridge Road Bend OR 01/07/22 01/07/22 9 PATIENT ADDRESS 123 Mountain Drive John Smith **Bend** ° OR d 10 BIRTHDATE 16 DHR 17 STAT DATE 13 HR 14 TYPE 15 SRC 1/1/57 OCCURRENCE SPAN OCCURRENCE SPAN OCCURRENCE CODE CODE CODE CODE 42 REV. CD. 43 DESCRIPTION 44 HCPCS / RATE / HIPPS CODE 45 SERV. DATE 46 SERV. UNITS 47 TOTAL CHARGES 48 NON-COVERED O XXXX 0490 Intraosseous des lumb/sacrum 64628 01/07/22 1 Intraosseous destruct add'l 01/07/22 1-2 XXXX 0490 64629 0278 Intracept Device(Probe & Access) C1889 01/07/22 2-4 XXXX Cost of Intracept device plus markup (consider the cost of additional level access its(s) if treating more than 2 VBs.) 64628 – Thermal destruction of intraosseous basivertebral nerve, inclusive of all imaging guidance; first two vertebral bodies, lumbar or sacral. 64629 - Thermal destruction of intraosseous basivertebral nerve, inclusive of all imaging guidance; each additional vertebral bodies, lumbar or sacral. PAGE OF **CREATION DATE TOTALS** 50 PAYER NAME 51 HEALTH PLAN ID 55 EST. AMOUNT DUE 56 NPI 57 Great Health Insurance Co. PPO73925 OTHER PRV ID 61 GROUP NAME 62 INSURANCE GROUP NO. 58 INSURED'S NAME 60 INSURED'S UNIQUE ID Jones. Macie KFJ123456789 654321 63 TREATMENT AUTHORIZATION CODES 64 DOCUMENT CONTROL NUMBER 65 EMPLOYER NAME A123456789 M54.51 CODE QUAI 76 ATTENDING FIRST OTHER PROCEDURE CODE DATE QUAL 77 OPERATING

Indications for Use: The IntraceptTM Intraosseous Nerve Ablation System is intended to be used in conjunction with radiofrequency (RF) generators for the ablation of basivertebral nerves of the L3 through S1 vertebrae for the relief of chronic low back pain of at least six months duration t hat has not responded to at least six months of conservative care, and is also accompanied by features consistent with Type 1 or Type 2 Modic changes on an MRI such as infla mmation, edema, vertebral endplate changes, disruption and fissuring of the endplate, vascularized fibrous tissues within the adjacent marrow, hypointensive signals (Type 1 Modic change), and changes to the vertebral body marrow including replacement of normal bone marrow by fat, and hyperintensive signals (Type 2 Modic change). Contraindications - Use of the Intracept Intraosseous Nerve Ablation System is contraindicated in: Patients with severe cardiac or pulmonary compromise, pat ients with active implantable pulse generators (e.g. pacemakers, defibrillators), patients where the targeted ablation zone is < 10 mm away from a sensitive structure not intended to be ablated, including the vertebral foramen (spinal canal), patients with active systemic infection or local infection in the area to be treated, p atients who are pregnant, and/or skeletally immature patients (generally ≤ 18 years of age). Refer to the Instructions for Use provided with the Intracept Procedure or www.relievant.com/intracept/ for potential adverse effects, warnings, and precautions prior to using this product.

Caution: U.S. Federal law restricts this device to sale by or on the order of a physician.

Disclaimer: Health economic and reimbursement information provided by Boston Scientific Corporation is gathered from third -party sources and is subject to change without notice as a result of complex and frequently changing laws, regulations, rules, and policies. This information is presented for illustrative purposes only and does not constitute reimbursement or legal advice. Boston Scientific encourages providers to submit accurate and appropriate claim s for services. It is always the provider's responsibility to determine medical necessity, the proper site for delivery of any services, and to submit appropriate codes, charges, and modifiers for services rendered. It is also always the provider's responsibility to understand and comply with Medicare national coverage determinations (NCD), Medicare local coverage determinations (LCD), and any other coverage requirements established by relevant payers which can be updated frequently. Boston Scientific recommends that you consult with your payers, reimbursement specialists, and/or legal counsel regarding coding, coverage, and reimbursement matters. Boston Scientific does not promote the use of its products outside their FDA- approved label. Payer policies will vary and should be verified prior to treatment for limitations on diagnosis, coding, or site of service requirements. All trademarks are the property of their respective owners. The coding options listed within this guide are com monly used codes and are not intended to be an all-inclusive list. We recommend consulting your relevant manuals for appropriate coding options. This coding information may include codes for procedures for which Boston Scientific currently offers no cleared or approved products. In those instances, such codes have been included so lely in the interest of providing users with comprehensive coding information and are not intended to promote the use of any Boston Scientific products for which they are not cleared or approved. The Health Care Provider (HCP) is solely responsible for

NM-2239802-AA Copyright © 2025 by Boston Scientific Corporation or its affiliates. All rights reserved.